- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions

European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
Pharmaceuticals - Community Register
Community register of medicinal products for human use |
AUTHORISED |
Product information |
| Invented name: | Mepact
|
| Auth. number : | EU/1/08/502 |
| Active substance : | mifamurtide |
| Orphan market exclusivity for "Treatment of osteosarcoma" (based on designation EU/3/04/206) started on 23/03/2009 10 years of market exclusivity This orphan market exclusivity will expire on 23/03/2019 | |
| ATC: | Anatomical main group: L - Antineoplastic and immunomodulating agents Therapeutic subgroup: L03 - Immunomodulating agents Pharmacological subgroup: L03A - Immunostimulating agents Chemical subgroup: L03AX - Other immunostimulating agents Chemical substance: L03AX15 - Mifamurtide (See WHO ATC Index) |
| Indication: | MEPACT is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with post-operative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients 2 to 30 years of age at initial diagnosis |
| Marketing Authorisation Holder: | Takeda France SAS
Immeuble Pacific, 11-13 cours Valmy, 92800 Puteaux, France |
|
EPAR and active package presentations | |
Package presentations | |
|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information". Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register. |
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 23/03/2009 | Centralised - Authorisation | EMEA/H/C/802 | (2009)1707 of 06/03/2009 | |||
| 04/01/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/802/IA/3 | ||||
| 04/01/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/802/IA/1 | ||||
| 04/01/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/802/IA/4 | ||||
| 04/01/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/802/IA/2 | ||||
| 04/01/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/802/IA/6 | ||||
| 04/01/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/802/IA/5 | ||||
| 19/01/2010 | Centralised - Variation | EMEA/H/C/802/IA/7 | ||||
| Updated with Decision(2010)5644 of 06/08/2010 | ||||||
| 31/03/2010 | Centralised - Variation | EMEA/H/C/802/IA/9 | ||||
| Updated with Decision(2010)5644 of 06/08/2010 | ||||||
| 26/07/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/802/IB/11 | ||||
| 27/07/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/802/IA/12 | ||||
| 29/07/2010 | Centralised - Variation | EMEA/H/C/802/IA/10/G | ||||
| Updated with Decision(2010)6902 of 30/09/2010 | ||||||
| 13/08/2010 | Centralised - Variation | (2010)5644 of 06/08/2010 | ||||
| 25/08/2010 | Centralised - Variation | EMEA/H/C/802/IA/14/G | ||||
| Updated with Decision(2010)6902 of 30/09/2010 | ||||||
| 06/10/2010 | Centralised - Variation | (2010)6902 of 30/09/2010 | ||||
| 15/12/2010 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/802/IA/13/G | ||||
| 31/01/2011 | Centralised - Variation | EMEA/H/C/802/IB/15 | ||||
| Updated with Decision(2011)6164 of 24/08/2011 | ||||||
| 04/02/2011 | Centralised - Variation (no change in Commission Decision) | EMEA/H/C/802/IB/16 | ||||
| 21/07/2011 | Centralised - Variation (refusal) | EMEA/H/C/802/IA/18 | ||||
| 30/08/2011 | Centralised - Variation | (2011)6164 of 24/08/2011 | ||||
| 01/06/2012 | Referral | EMEA/H/C/802/A-20/22 | (2012)3588 of 25/05/2012 | |||
| 27/08/2012 | Centralised - Variation | EMEA/H/C/802/II/24 | (2012)6024 of 23/08/2012 | |||
| 26/09/2012 | Corrigendum | (2012)6853 of 24/09/2012 | ||||
| 17/01/2013 | Centralised - Variation | EMEA/H/C/802/II/25 | ||||
| Updated with Decision(2013)5789 of 05/09/2013 | ||||||
| 21/03/2013 | Centralised - Variation | EMEA/H/C/802/II/26 | ||||
| Updated with Decision(2013)5789 of 05/09/2013 | ||||||
| 10/06/2013 | Centralised - Variation | EMEA/H/C/802/IAin/33 | ||||
| Updated with Decision(2013)5789 of 05/09/2013 | ||||||
| 09/09/2013 | Centralised - Transfer Marketing Authorisation Holder | EMEA/H/C/802/T/35 | (2013)5789 of 05/09/2013 | |||
| 23/12/2013 | Centralised - Renewal | EMEA/H/C/802/R/34 | (2013)9751 of 18/12/2013 | |||
| 17/12/2015 | Centralised - Variation | EMEA/H/C/802/IAin/40/G | ||||
| Updated with Decision(2016)9023 of 23/12/2016 | ||||||
| 14/12/2016 | Centralised - Variation | EMEA/H/C/000802/IAIN/0044/G | ||||
| 04/01/2017 | Centralised - Yearly update | (2016)9023 of 23/12/2016 |


